Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkβ-dependent induction of hTERT due to down-regulation of Pin1 transcription

Hematology

Volumn 17, Issue 4, 2012, Pages 198-206

  Ghaffari, Seyed H ^a   Momeny, Majid ^a   Bashash, Davood ^a,b   Mirzaei, Roohollah ^a   Ghavamzadeh, Ardeshir ^a   Alimoghaddam, Kamran ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute promyelocytic leukemia; Arsenic trioxide; Nuclear factor kappa B; Pin1; PinX1

Indexed keywords

ARSENIC TRIOXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MYC PROTEIN; PEPTIDYLPROLYL ISOMERASE PIN1; PROTEIN P73; SURVIVIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVITY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE 1 GENE; LEUKEMIA CELL; LEUKEMIA CELL LINE; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; P73 GENE; PIN1 GENE; PINX1 GENE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SURVIVIN GENE; TELOMERASE REVERSE TRANSCRIPTASE GENE; TELOMERE SHORTENING; TRANSCRIPTION REGULATION; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1 GENE;

APOPTOSIS; ARSENICALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, MYC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NF-KAPPA B; NUCLEAR PROTEINS; OXIDES; PEPTIDYLPROLYL ISOMERASE; PHOSPHORYLATION; TELOMERASE; TELOMERE SHORTENING; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84866065183     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845412Y.0000000008     Document Type: Article

References (30)

1. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood. 1999;94(1):12-22.
2. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Farretta M, et al. Methyltransferase recruitment and DNA hypermethy- lation of target promoters by an oncogenic transcription factor. Science. 2002;295(5557):1079-82.
3. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or che- motherapy. Ann Oncol. 2006;17(1):131-4.
4. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood. 1999;94(6):2102-11.
5. Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res. 1999;59(4):776-80.
6. Rousselot P, Labaume S, Maroleau JP, Larghero J, Noguera MH, Brouet JC, et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res. 1999;59(5):1041-8.
7. Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett. 1999;455(1-2):59-62.
8. Huang XJ, Wiernik PH, Klein RS, Gallagher RE. Arsenic triox-ide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol. 1999;16(1):58-64.
9. Zhang X, Multani AS, Zhou JH, Shay JW, McConkey D, Dong L, et al. Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells. Cancer Res. 2003;63(4): 760-5.
10. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1): 33-40.
11. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol. 2006; 18(6):609-15.
12. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA. 2002;99(7):4349-54.
13. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8(1):61-70.
14. Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G, et al. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell. 2003;12(6):1413-26.
15. Atkinson GP, Nozell SE, Harrison DK, Stonecypher MS, Chen D, Benveniste EN. The prolyl isomerase Pin1 regulates the NF-kappaB signaling pathway and interleukin-8 expression in glioblastoma. Oncogene. 2009;28(42):3735-45.
16. Hausladen DA, Wheeler MA, Altieri DC, Colberg JW, Weiss RM. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome. J Urol. 2003;170(1):230-4.
17. Ghaffari SH, Rostami S, Bashash D, Alimoghaddam K, Ghavamzadeh A. Real-time PCR analysis of PML-RAR alpha in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy. Ann Oncol. 2006;7(10):1553-9.
18. Miller WH, Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002; 62(14):3893-903.
19. de The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010; 10(11):775-83.
20. 3. Cancer Cell. 2010;18(1):88-98.
21. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol. 2008;10(5):547-55.
22. Rojewski MT, Korper S, Schrezenmeier H. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. Leuk Lymphoma. 2004;45(12):2387-401.
23. Zhou C, Boggess JF, Bae-Jump V, Gehrig PA. Induction of apoptosis and inhibition of telomerase activity by arsenic triox- ide (As2O3) in endometrial carcinoma cells. Gynecol Oncol. 2007;105(1):218-22.
24. Kamihira S, Yamada Y, Hirakata Y, Tomonaga M, Sugahara K, Hayashi T, et al. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis. Br J Haematol. 2001;114(1):63-9.
25. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6(1): 127-34.
26. Endoh T, Tsuji N, Asanuma K, Yagihashi A, Watanabe N. Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription. Exp Cell Res. 2005;305(2): 300-11.
27. Chen J, Wu W, Tahir SK, Kroeger PE, Rosenberg SH, Cowsert LM, et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage- independent growth. Neoplasia. 2000;2(3):235-41.
28. Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, et al. Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery. 2005;138(2):299-305.
29. Beitzinger M, Oswald C, Beinoraviciute-Kellner R, Stiewe T. Regulation of telomerase activity by the p53 family member p73. Oncogene. 2006;25(6):813-26.
30. Zhang B, Bai YX, Ma HH, Feng F, Jin R, Wang ZL, et al. Silencing PinX1 compromises telomere length maintenance as well as tumorigenicity in telomerase-positive human cancer cells. Cancer Res. 2009;69(1):75-83.